T. Holdich

发表

A Randomized, Double-blind, Placebo-controlled, Ascending-dose Tolerability and Safety Study of Remacemide as Adjuvant Therapy in Parkinson's Disease with Response Fluctuations

C. Clarke, J. Cooper, T. Holdich, 2001, Clinical neuropharmacology.

Effect of Lamivudine on the Plasma and Intracellular Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers

T. Holdich, J. Sawyer, L. Shiveley, 2007, Antimicrobial Agents and Chemotherapy.

Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.

P. Keith, W. Aberer, F. Horak, 2011, Allergy and asthma proceedings.

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.

P. Patel, T. Holdich, K. J. Fischer von Weikersthal-Drachenberg, 2014, The Journal of allergy and clinical immunology.

A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment

S. Schachter, O. Devinsky, I. Leppik, 2002, Seizure.

Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg / day) in a Q.I.D. regimen

D. Chadwick, T. Betts, I. Soryal, 2002, Seizure.

Remacemide versus carbamazepine in newly diagnosed epilepsy

J. Whitehead, M. Brodie, S. Wroe, 2002, Epilepsy & Behavior.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

Daniel K. Wells, S. Grupp, W. Tap, 2018, Cancer discovery.

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma

J. E. Brewer, B. Levine, M. Kalos, 2015, Nature Medicine.

Pharmacokinetics of Single Oral Doses of Apricitabine, a Novel Deoxycytidine Analogue Reverse Transcriptase Inhibitor, in Healthy Volunteers

T. Holdich, J. Sawyer, L. Shiveley, 2006, Clinical drug investigation.

Examination of some factors responsible for a food-induced increase in absorption of atovaquone.

B. Weatherley, P. Rolan, J. Posner, 1994, British journal of clinical pharmacology.

Multiple-Dose Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with HIV-1 Infection

P. Cahn, M. Rolón, I. Cassetti, 2008, Clinical drug investigation.

Pharmacokinetics and tolerability of single oral doses of 882C87, a potent, new anti-varicella-zoster virus agent, in healthy volunteers

B. Weatherley, P. Crome, J. Posner, 1995, Antimicrobial agents and chemotherapy.

Influence of food on the pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor

T. Holdich, J. Sawyer, 2008 .

Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer

Matthew J. Frigault, R. Govindan, Melissa L. Johnson, 2022, Journal for ImmunoTherapy of Cancer.

566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.

W. Gutteridge, A. Hudson, T. Holdich, 1991, Drugs under experimental and clinical research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma

Melissa L. Johnson, D. Hong, K. Odunsi, 2019, Annals of Oncology.

Significant Reduction In Combined Symptom And Medication Score Compared With Placebo Following MPL-Adjuvanted uSCIT In Patients With Seasonal Grass Pollen Allergy

L. Dubuske, M. Castells, T. Holdich, 2009 .

Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis

J. Whitehead, M. Brodie, S. Wroe, 2002, Epilepsy & Behavior.

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson’s disease

L. Seeberger, E. Siemers, C. Adler, 2001, Neurology.

Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.

P. Keith, W. Aberer, F. Horak, 2011, Allergy and asthma proceedings.

Phase I/IIa Study of Genetically Engineered NY-ESO-1 SPEAR T-Cells Administered Following Autologous Stem Cell Transplant in HLA-a*02+ Patients with Advanced Multiple Myeloma: Long Term Follow-up (NCT01352286)

A. Rapoport, R. Amado, E. Stadtmauer, 2017 .

Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)

S. Grupp, C. Mackall, G. Kari, 2016 .

Autologous genetically engineered NY-ESO-1c259T in HLA-A*02:01, HLA*02:05 and HLA*02:06 positive patients with NY-ESO-1 expressing tumors.

G. Linette, S. Grupp, H. Kluger, 2016 .

Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.

R. Sullivan, R. Govindan, Melissa L. Johnson, 2018 .

Cytokine release syndrome (CRS) in patients treated with NY-ESO-1c259 TCR.

K. Odunsi, C. Mackall, G. Kari, 2016 .

Genetically engineered NY-ESO-1 specific T cells in HLA-A201+ patients with advanced cancers.

S. Grupp, B. Jakobsen, W. Tap, 2015 .

Significant Reduction In Combined Symptom And Medication Score Compared With Placebo With A Ragweed uSCIT Formulation For Seasonal Pollen Allergy

T. Casale, P. Keith, H. Kaiser, 2009 .

Optimizing engineered TCR T cell therapy for synovial sarcoma

B. Jakobsen, W. Tap, C. Mackall, 2015, Journal of Immunotherapy for Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg / day) in a Q.I.D. regimen

T. Holdich, D. Chadwick, T.A Betts, 2002, Seizure.

Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen.

P. Keith, W. Aberer, F. Horak, 2011, Allergy and asthma proceedings.